Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jun 2;83(1):91–94. doi: 10.1054/bjoc.2000.1196

Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma

R Saso 1, S Kulkarni 2, P Mitchell 3, J Treleaven 1, G J Swansbury 4, J Mehta 5, R Powles 2, S Ashley 6, R Kuan 7, T Powles 2
PMCID: PMC2374543  PMID: 10883674

Abstract

Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years. Median duration of survival from diagnosis of MDS/AML was 10 months and six patients died. The crude incidence of developing MDS/AML after MMM or MM chemotherapy was 15 per 100 000 patient years follow-up, while the actuarial risk was 1.1% and 1.6% at 5 and 10 years respectively. MTZ-based regimens carry a 10 × higher risk of subsequent MDS/AML compared to that seen in the general population. © 2000 Cancer Research Campaign

Keywords: myelodysplastic syndrome, acute myeloid leukaemia, breast cancer, mitoxantrone

Full Text

The Full Text of this article is available as a PDF (52.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aul C., Gattermann N., Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992 Oct;82(2):358–367. doi: 10.1111/j.1365-2141.1992.tb06430.x. [DOI] [PubMed] [Google Scholar]
  2. Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982 Jun;51(2):189–199. [PubMed] [Google Scholar]
  3. Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985 Oct;103(4):620–625. doi: 10.7326/0003-4819-103-4-620. [DOI] [PubMed] [Google Scholar]
  4. Bonadonna G., Valagussa P., Moliterni A., Zambetti M., Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995 Apr 6;332(14):901–906. doi: 10.1056/NEJM199504063321401. [DOI] [PubMed] [Google Scholar]
  5. Breslow N. E., Day N. E. Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. IARC Sci Publ. 1987;(82):1–406. [PubMed] [Google Scholar]
  6. Diamandidou E., Buzdar A. U., Smith T. L., Frye D., Witjaksono M., Hortobagyi G. N. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 1996 Oct;14(10):2722–2730. doi: 10.1200/JCO.1996.14.10.2722. [DOI] [PubMed] [Google Scholar]
  7. Ellis M., Ravid M., Lishner M. A comparative analysis of alkylating agent and epipodophyllotoxin-related leukemias. Leuk Lymphoma. 1993 Sep;11(1-2):9–13. doi: 10.3109/10428199309054725. [DOI] [PubMed] [Google Scholar]
  8. Fisher B., Dignam J., Wolmark N., DeCillis A., Emir B., Wickerham D. L., Bryant J., Dimitrov N. V., Abramson N., Atkins J. N. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997 Nov 19;89(22):1673–1682. doi: 10.1093/jnci/89.22.1673. [DOI] [PubMed] [Google Scholar]
  9. Henderson I. C., Garber J. E., Breitmeyer J. B., Hayes D. F., Harris J. R. Comprehensive management of disseminated breast cancer. Cancer. 1990 Sep 15;66(6 Suppl):1439–1448. doi: 10.1002/1097-0142(19900915)66:14+<1439::aid-cncr2820661421>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  10. Johansson B., Mertens F., Mitelman F. Primary vs. secondary neoplasia-associated chromosomal abnormalities--balanced rearrangements vs. genomic imbalances? Genes Chromosomes Cancer. 1996 Jul;16(3):155–163. doi: 10.1002/(SICI)1098-2264(199607)16:3<155::AID-GCC1>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  11. Montes A., Powles T. J., O'Brien M. E., Ashley S. E., Luckit J., Treleaven J. A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. Eur J Cancer. 1993;29A(13):1854–1857. doi: 10.1016/0959-8049(93)90537-p. [DOI] [PubMed] [Google Scholar]
  12. Pedersen-Bjergaard J., Rowley J. D. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood. 1994 May 15;83(10):2780–2786. [PubMed] [Google Scholar]
  13. Philpott N. J., Bevan D. H., Gordon-Smith E. C. Secondary leukaemia after MMM combined modality therapy for breast carcinoma. Lancet. 1993 May 15;341(8855):1289–1289. doi: 10.1016/0140-6736(93)91199-v. [DOI] [PubMed] [Google Scholar]
  14. Powles T. J., Hickish T. F., Makris A., Ashley S. E., O'Brien M. E., Tidy V. A., Casey S., Nash A. G., Sacks N., Cosgrove D. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 1995 Mar;13(3):547–552. doi: 10.1200/JCO.1995.13.3.547. [DOI] [PubMed] [Google Scholar]
  15. Powles T. J., Jones A. L., Judson I. R., Hardy J. R., Ashley S. E. A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. Br J Cancer. 1991 Aug;64(2):406–410. doi: 10.1038/bjc.1991.318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rustin G. J., Newlands E. S., Lutz J. M., Holden L., Bagshawe K. D., Hiscox J. G., Foskett M., Fuller S., Short D. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol. 1996 Oct;14(10):2769–2773. doi: 10.1200/JCO.1996.14.10.2769. [DOI] [PubMed] [Google Scholar]
  17. Skuse G. R., Ludlow J. W. Tumour suppressor genes in disease and therapy. Lancet. 1995 Apr 8;345(8954):902–906. doi: 10.1016/s0140-6736(95)90015-2. [DOI] [PubMed] [Google Scholar]
  18. Smith M. A., McCaffrey R. P., Karp J. E. The secondary leukemias: challenges and research directions. J Natl Cancer Inst. 1996 Apr 3;88(7):407–418. doi: 10.1093/jnci/88.7.407. [DOI] [PubMed] [Google Scholar]
  19. Tallman M. S., Gray R., Bennett J. M., Variakojis D., Robert N., Wood W. C., Rowe J. M., Wiernik P. H. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol. 1995 Jul;13(7):1557–1563. doi: 10.1200/JCO.1995.13.7.1557. [DOI] [PubMed] [Google Scholar]
  20. Thirman M. J., Larson R. A. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am. 1996 Apr;10(2):293–320. doi: 10.1016/s0889-8588(05)70340-3. [DOI] [PubMed] [Google Scholar]
  21. Williamson P. J., Kruger A. R., Reynolds P. J., Hamblin T. J., Oscier D. G. Establishing the incidence of myelodysplastic syndrome. Br J Haematol. 1994 Aug;87(4):743–745. doi: 10.1111/j.1365-2141.1994.tb06733.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES